Numerous studies have explored the utilization of early biomarkers of AKI, such as NGAL and the recent combination of tissue inhibitor of metalloproteinase-2 and urine insulin-like growth factor-binding protein 7, in critically ill patients during the last decade [53–59]. The gene discussed is LCN2; the disease is acute kidney injury.